In lymphoid neoplasms, CD147 has been observed to increase resistance to chemotherapy drugs through the formation of a complex consisting of CD147, the endothelial lymphatic vessel hyaluronic acid receptor-1 (LYVE-1), and a drug transporter known as breast cancer-resistance protein/ABCG2 (BCRP), located on the cell surface of a primary effusive lymphoma tumor cell line (PEL). Here, BSG is linked to lymphoid neoplasm.